Overcoming barriers to HPV vaccination: Non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months

Vaccine

Volumn 32, Issue 6, 2014, Pages 725-732

  Lazcano Ponce, Eduardo ^a   Stanley, Margaret ^b   Muñoz, Nubia ^c   Torres, Leticia ^a   Cruz Valdez, Aurelio ^a   Salmerón, Jorge ^a,d   Rojas, Rosalba ^a   Herrero, Rolando ^e   Hernández Ávila, Mauricio ^a  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Instituto Nacional de Cancerología   (Colombia)

^d INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^e INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

HPV 16 18 vaccine; Immunization schedule; Immunogenicity; Non inferiority trial

Indexed keywords

HUMAN PAPILLOMAVIRUS TYPE 18 VACCINE; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CHILD; DOSE RESPONSE; DRUG DOSE REGIMEN; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS VACCINATION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCHOOL CHILD; VACCINATION; YOUNG ADULT;

HPV-16/18 VACCINE; IMMUNIZATION SCHEDULE; IMMUNOGENICITY; NON-INFERIORITY TRIAL;

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; IMMUNIZATION SCHEDULE; MEXICO; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84893009653     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.11.059     Document Type: Article

References (26)

1. Tota J.E., Chevarie-Davis M., Richardson L.A., Devries M., Franco E.L. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med 2011, 53:S12-S21.
2. Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Garland S.M., Castellsagué X., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:89-99.
3. Muñoz N., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010, 102:325-339.
4. Schwarz T.F., Huang L.M., Medina D.M., Valencia A., Lin T.Y., Behre U., et al. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years. J Adolesc Health 2012, 50:187-194.
5. Price is the main barrier to wider use of papillomavirus vaccine 2013, Sabin Vaccine Institute, http://www.sabin.org/updates/news/price-main-barrier-wider-use-papillomavirus-vaccine [consulted June 2013].
6. Centers for Disease Control and Prevention (CDC) Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013-United States. MMWR Morb Mortal Wkly Rep 2013, 62:591-595.
7. Almonte M., Murillo R., Sánchez G.I., Jerónimo J., Salmerón J., Ferreccio C., et al. New paradigms and challenges in cervical cancer prevention and control in Latin America. Salud Publica Mex 2010, 52:544-559.
8. Romanowski B., Schwarz T.F., Ferguson L.M., Peters K., Dionne M., Schulze K., et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccine 2011, 7:1374-1386.
9. Neuzil K.M., Canh do G., Thiem V.D., Janmohamed A., Huong V.M., Tang Y., et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA 2011, 305:1424-1431.
10. Reisinger K.S., Block S.L., Lazcano-Ponce E., Samakoses R., Esser M.T., Erick J., et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007, 26:201-209.
11. Block S.L., Nolan T., Sattler C., Barr E., Giacoletti K.E., Marchant C.D., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006, 118:2135-2145.
12. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M., et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011, 103:1444-1451.
13. Dobson S.R., McNeil S., Dionne M., Dawar M., Ogilvie G., Krajden M., et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs. 3 doses in young women: a randomized clinical trial. JAMA 2013, 309:1793-1802.
14. Lamontagne D.S., Thiem V.D., Huong V.M., Tang Y., Neuzil K.M. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose. J Infect Dis 2013, 208:1325-1334.
15. Office fédéral de la santé publique, Commission fédérale pour les vaccinations Plan de vaccination suisse 2012. Directives et recommandations 2012, Office fédéral de la santé publique, Berne.
16. Kuehn B.M. Two doses of HPV vaccine may be sufficient. JAMA 2011, 306:1643.
17. Duval B., Sauvageau C., Boulianne N., Gilca V., Comité sur l'immunisation du Québec Vaccination against human papillomaviruses. Perspect Infirm 2009, 6. pp. 49-50, 52.
18. Lazcano-Ponce E., Salmerón-Castro J., García-Carrancá A., Aranda-Flores C., Madrid-Marina V., Gómez-Altamirano C.M., et al. Recommendations for the definition of a policy on vaccination against papillomavirus in Mexico. Strategic Advisory Group of Experts of the World Health Organization. Salud Publica Mex 2009, 51:336-341.
19. Bissett S.L., Wilkinson D., Tettmar K.I., Jones N., Stanford E., Panicker G., et al. Human papillomavirus antibody reference reagents for use in postvaccination surveillance serology. Clin Vaccine Immunol 2012, 19:449-451.
20. Deschuyteneer M., Elouahabi A., Plainchamp D., Plisnier M., Soete D., Corazza Y., et al. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Hum Vaccine 2010, 6:407-419.
21. Dessy F.J., Giannini S.L., Bougelet C.A., Kemp T.J., David M.P., Poncelet S.M., et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccine 2008, 4:425-434.
22. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmerón J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double blind, randomised controlled trial. Lancet 2007, 369:2161-2170.
23. GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B., de Borba P.C., Naud P.S., Roteli-Martins C.M., De Carvalho N.S., et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomized placebo-controlled trial up to 6.4 years. Lancet 2009, 374:1975-1985.
24. De Carvalho N., Teixeira J., Roteli-Martins C.M., Naud P., De Borba P., Zahaf T., et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010, 28:6247-6255.
25. Esposito S., Birlutiu V., Jarcuska P., Perino A., Man S.C., Vladareanu R., et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study. Pediatr Infect Dis J 2011, 30:e49-e55.
26. Stephen K., Obaro S.K., Ota M.O. Sense and the science of childhood immunization: can we achieve more with less. Vaccine 2006, 24:6460-6467.